(Q53105911)

11 May 2018

meta-analysis

0 references

title

Non-inferiority trials in breast and non-small cell lung cancer: choice of non-inferiority margins and other statistical aspects. (English)

1 reference

11 May 2018

0 references

Everardo D Saad

1

1 reference

11 May 2018

Marc Buyse

series ordinal

2

1 reference

11 May 2018

publication date

1 September 2012

1 reference

11 May 2018

published in

Acta Oncologica

1 reference

11 May 2018

volume

51

1 reference

11 May 2018

issue

7

1 reference

11 May 2018

page(s)

890-896

1 reference

11 May 2018

Design and analysis of non-inferiority mortality trials in oncology.

cites work

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.702924

Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.702924

Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.702924

A regulatory perspective on choice of margin and statistical inference issue in non-inferiority trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.702924

Active-controlled, non-inferiority trials in oncology: arbitrary limits, infeasible sample sizes and uninformative data analysis. is there another way?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.702924

Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.702924

Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.702924

Choice of delta: requirements and reality--results of a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.702924

Quality of reporting of noninferiority and equivalence randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.702924

Efficacy of experimental treatments compared with standard treatments in non-inferiority trials: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.702924

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.702924

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.702924

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.702924

Statistical considerations in the intent-to-treat principle

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.702924

A comparison of intent-to-treat and per-protocol results in antibiotic non-inferiority trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.702924

10.3109/0284186X.2012.702924

21 January 2018

Identifiers

DOI

1 reference

11 May 2018

release_hfkkrpcg2zesxkkk74oqnrs25e

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hfkkrpcg2zesxkkk74oqnrs25e

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

11 May 2018